Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40(3):250–60.

Article  PubMed  Google Scholar 

Conti CB, Agnesi S, Scaravaglio M, Masseria P, Dinelli ME, Oldani M, et al. Early gastric cancer: update on prevention, diagnosis and treatment. Int J Environ Res Public Health. 2023;20(3):2149.

Article  PubMed  PubMed Central  Google Scholar 

Valentini V, Cellini F, Minsky BD, Mattiucci GC, Balducci M, D’Agostino G, et al. Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. Radiother Oncol. 2009;92(2):176–83.

Article  PubMed  Google Scholar 

Moertel CG, Childs DS, Jr Reitemeier RJ, Colby MY, Jr., Holbrook M A,. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2(7626):865–7.

Article  CAS  PubMed  Google Scholar 

Schein PS. A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Gastrointestinal Tumor Study Group Cancer. 1982;49(9):1771–7.

Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

Article  CAS  PubMed  Google Scholar 

Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–42.

Article  CAS  PubMed  Google Scholar 

Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73.

Article  PubMed  Google Scholar 

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.

Article  CAS  PubMed  Google Scholar 

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.

Article  CAS  PubMed  Google Scholar 

Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020;23(3):510–9.

Article  CAS  PubMed  Google Scholar 

Yamaba Y, Takakuwa O, Tomita Y, Owaki S, Yamada K, Kunii E, et al. Mycobacterium avium complex lung disease in a patient treated with an immune checkpoint inhibitor: a case report. Mol Clin Oncol. 2022;16(2):37.

Article  PubMed  Google Scholar 

Tanabe K, Kanzaki H, Wada T, Nakashima Y, Sugiyama H, Okada H, et al. Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer: a case report. Medicine (Baltimore). 2020;99(21):e20464.

Article  PubMed  Google Scholar 

Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol. 2021;18(8):473–87.

Article  PubMed  Google Scholar 

Shi T, Zhang Y, Wang Y, Song X, Wang H, Zhou X, et al. DKK1 promotes tumor immune evasion and impedes Anti-PD-1 treatment by Inducing Immunosuppressive macrophages in gastric cancer. Cancer Immunol Res. 2022;10(12):1506–24.

Article  CAS  PubMed  Google Scholar 

Scott LJ. apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs. 2018;78(7):747–58.

Article  CAS  PubMed  Google Scholar 

Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: a review. Crit Rev Food Sci Nutr. 2018;58(9):1428–47.

Article  PubMed  Google Scholar 

Janjigian YY, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

ZW25 Effective in HER2-Positive Cancers. Cancer Discov. 2019; 9(1):8.

Long B, Qin L, Zhang B, Li Q, Wang L, Jiang X, et al. CAR T-cell therapy for gastric cancer: potential and perspective (review). Int J Oncol. 2020;56(4):889–99.

CAS  PubMed  Google Scholar 

Sun J, Li X, Chen P, Gao Y. From anti-HER-2 to anti-HER-2-CAR-T CELLS: an evolutionary immunotherapy approach for gastric cancer. J Inflamm Res. 2022;15:4061–85.

Article  PubMed  PubMed Central  Google Scholar 

Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117(12):1736–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, et al. Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther. 2017;11:2265–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chalouni C, Doll S. Fate of antibody-drug conjugates in cancer cells. J Exp Clin Cancer Res. 2018;37(1):20.

Article  PubMed  PubMed Central  Google Scholar 

Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody-drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3–19.

Article  CAS  PubMed  Google Scholar 

Correia IR. Stability of IgG isotypes in serum. MAbs. 2010;2(3):221–32.

Article  PubMed  PubMed Central  Google Scholar 

Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–37.

Article  CAS  PubMed  Google Scholar 

Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 2016;76(9):2710–9.

Article  CAS  PubMed  Google Scholar 

Puthenveetil S, Loganzo F, He H, Dirico K, Green M, Teske J, et al. natural product splicing inhibitors: a new class of antibody-drug conjugate (ADC) payloads. Bioconjug Chem. 2016;27(8):1880–8.

Article  CAS  PubMed  Google Scholar 

Shitara KT, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18(11):1512–22.

Article  PubMed  Google Scholar 

Tsurutani J, Iwata H, Krop I, Janne PA, Takahashi ST, et al. Targeting HER2 with Trastuzumab deruxtecan: a dose-expansion, phase I study in Multiple advanced solid tumors. Cancer Discov. 2020;10(5):688–701.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meric-Bernstam F, Calvo E, Lee KS, Moreno V, Park YH, Rha SY, et al. Safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-expressing solid tumors: a phase 1 dose-escalation study. Mol Cancer Ther. 2023;22(10):1191–203.

Article